{"id":324529,"date":"2022-10-09T13:39:54","date_gmt":"2022-10-09T11:39:54","guid":{"rendered":"https:\/\/medizinonline.com\/the-treatment-of-r-r-cll-guidelines-studies-and-case-reports\/"},"modified":"2022-10-09T13:39:54","modified_gmt":"2022-10-09T11:39:54","slug":"the-treatment-of-r-r-cll-guidelines-studies-and-case-reports","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/the-treatment-of-r-r-cll-guidelines-studies-and-case-reports\/","title":{"rendered":"The treatment of R\/R CLL: guidelines, studies and case reports."},"content":{"rendered":"

The development of new, targeted substances can replace classic chemotherapies with more tolerable approaches<\/strong>
\n 1<\/sup>
\n<\/strong>. In this webcast, Marc Heizmann, MD, Senior Physician Hematology and Transfusion Medicine at the Cantonal Hospital Aarau, talks about the treatment guidelines for R\/R CLL, presents studies on targeted therapy and presents two case reports. <\/strong><\/p>\n

<\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

 <\/p>\n

\"\"<\/p>\n